Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Sanofi to invest €350m in new Canadian vaccine plant

Sanofi has announced plans to spend €350 million on a new vaccine facility located in Toronto, Canada, a move which, according to the company, is one of its biggest-ever investments in a single building.

 

Bron: Pharmafile Meer lezen »

Alzheimer’s protein treatment that works in human cells

One of the major stumbling blocks that science has come up against, when trying to develop potential treatments for Alzheimer’s disease, is that promising trials results in mice have not translated so successfully into human studies.

Bron: Pharmafile Meer lezen »

Bayer contraceptive implant public backlash brings results

Bayer’s permanent contraceptive device, Essure, has been at the centre of a public backlash for a number of years, with women how had the device implanted suggesting that they were had not been made aware of the risks.

Bron: Pharmafile Meer lezen »

Lilly and Sigilon team up in $473m+ deal to ‘cure’ diabetes

Eli Lilly and Sigilon Therapeutics have announced a partnership that looks to break new ground in the management of type 1 diabetes, by using stem cells to provide a long-term treatment solution.

 

Bron: Pharmafile Meer lezen »

Ionis may get up to $300 million in licensing deal with AstraZeneca

Ionis Pharmaceuticals Inc said on Monday a licensing deal for its fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.

Bron: Reuters Meer lezen »

Merck’s Keytruda meets main goal in pivotal lung cancer trial

Merck & Co said a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade.

Bron: Reuters Meer lezen »

Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar

Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie which grants patent licenses for the sale of the product in Europe and the US, and stipulates that the three parties agree to dismiss any ongoing litigation surrounding the issue.

Bron: Pharmafile Meer lezen »

Roche suffers Ocrevus knockback by NICE

Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, as it managed to bring in $902 million in sales during the 2017 financial year.

 

Bron: Pharmafile Meer lezen »

Takeda move for Shire looks increasingly likely

Takeda’s surprise announcement that it was weighing up a move for Shire had some analysts sceptical about whether the Japanese company could pull off such a larger acquisition.

 

Bron: Pharmafile Meer lezen »

J&J pays out $37m in damages over claims its talc contains asbestos

Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out $37 million in damages after losing the first trial in a legal dispute which alleges that its Baby Powder product contains the carcinogenic ingredient asbestos.

Bron: Pharmafile Meer lezen »